Sie suchten nach: cross reactive (Englisch - Maltesisch)

self-reactive substance
sustanza awtoreattiva

reactive power device
apparat ta’ potenza reattiva

c-reactive protein increased
Żieda fi proteina reattiva Ċ

machines for processing reactive resins
magni għall-ipproċessar ta rażi reattivi

reactive dyes and preparations based thereon
Żebgħat reattivi u preparazzjonijiet ibbażati fuqhom

demand side response reactive power control
kontroll tal-potenza reattiva għar-respons tad-domanda

cross-reactive immune response against variants of a/ vietnam/ 1194/ 2004 (h5n1):
respons immuni cross- reactive kontra varjanti ta ’ a/ vietnam/ 1194/ 2004 (h5n1):

c-reactive protein increased blood calcium decreased
Żieda fil-proteina reattiva c tnaqqis tal-kalċju fid-demm

implementation of reactive power compensation equipment (nl)
implimentazzjoni ta' tagħmir ta' kompensazzjoni ta' l-enerġija reattiva (nl)

in this study, cross-reactive immune responses against a/indonesia/5/2005 were also observed.
f’dan l-istudju, ġew osservati wkoll risponsi immuni ta’ kross-reattività kontra a/indonesia/5/2005.

c-reactive protein increased, blood parathyroid hormone increased
żieda fil-proteina Ċ-reattiva, żieda fl-ormon tal-paratirojde fid-demm,

increased protein (c-reactive protein) in blood indicating inflammation
Żieda fil-proteini (proteina ċ-reattiva) fid-demm li tindika infjammazzjoni

rare semen analysis abnormal, c-reactive protein increased, blood calcium decreased
analiżi tas-semen mhux normali, żieda fil-proteina reattiva Ċ, tnaqqis tal-kalċju fid-demm

serum sickness, anaphylactoid reactions, cross reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*
mard minn serum, reazzjonijiet anafilattojdi, reazzjoni ta’ sensittività eċċessiva li hija komuni għat-tipi differenti ta’ thienopyridines (bħal ticlopidine, prasugrel) (ara sezzjoni 4.4)

serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*
mard minn seru barrani, reazzjonijiet anafilattiċi, reazzjoni ta’ sensittività eċċessiva li hija komuni għat-tipi differenti ta’ thienopyridines (bħal ticlopidine, prasugrel) (ara sezzjoni 4.4)

cross-reactive immune responses elicited by a version of arepanrix containing 3.75 µg ha derived from a/indonesia/05/2005 (h5n1):
rispons immuni cross-reactive li rriżulta minn verżjoni ta’ arepanrix li fiha 3.75 µg ha derivat minn a/indonesia/05/2005 (h5n1):

cross-reactive immune response elicited by as03-adjuvanted vaccine containing 3.75 µg ha derived from a/indonesia/05/2005 (h5n1)
respons immuni cross-reactive misluta minn vaccin stimulat b’as03 li fih 3.75μg ha derivat minn a/indonesia/05/2005 (h5n1)

similar antibody gmcs and opa gmts were observed for all infants except lower antibody gmcs for serotypes 4, 5, 9v and the cross-reactive serotype 19a in very preterms and serotype 9v in preterms and lower opa gmt for serotype 5 in very preterms.
gmcs ta’ antikorpi u gmts ta’ opa jixxiebhu kienu osservati għat-trabi kollha minbarra gmcs aktar baxxi ta’ antikorpi għas-serotipi 4, 5,9v u s-serotip kross-reattiv 19a fi trabi li twieldu ħafna qabel iż- żmien, u s-serotip 9v fit-trabi li twieldu qabel iż-żmien u gmt aktar baxx ta’ opa għas-serotip 5 fi trabi li twieldu ħafna qabel iż-żmien.

there is insufficient evidence that synflorix provides protection against pneumococcal serotypes not contained in the vaccine except the cross-reactive serotype 19a (see section 5.1) or against non- typeable haemophilus influenzae.
m’hemmx biżżejjed evidenza li synflorix jipporovdi protezzjoni kontra serotipi pnewmokokkali li ma jinstabux fit-tilqima ħlief is-serotip kross-reattiv 19a (ara sezzjoni 5.1) jew kontra non-typeable haemophilus influenzae.

hyperbilirubinaemia*, protein analyses abnormal*, weight increased, blood test abnormal*, c-reactive protein increased
iperbilirubinemija*, valuri anormali tal-analiżi ta’ proteini*, Żieda fil-piż, valuri anormali tat-testijiet tad- demm*, Żieda fil-proteina li tirreaġixxi ma’ c